| DATE: August 7, 2025 | | |
| --- | --- | --- |
| **TOPIC** | **DISCUSSION/ACTION** | **FOLLOW-UP** |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a poll link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Strawpoll sent with these minutes.  <https://strawpoll.com/B2ZB9vK7BgJ> |
| ClinPGx/PGRN CPIC 2025 Meeting Updates and Reminders | Meeting Registration: <https://www.pgrn.org/event-5921668>   * 1. **CPIC Member discount code (for members that are not PGRN members):** CPICPGRNMT2025;   2. Register by September 3 to get advanced registration rate.   3. Reserve your hotel now. Hotel blocks are posted to the registration site. | Register for meeting.  <https://www.pgrn.org/event-5921668> |
| Guidelines In-progress | Guidelines   * *CYP3A5*/Tacrolimus – In evidence review * *CYP2D6*/Antipsychotics – CYP2D6: Drafted 3 recommendations and working on the rest; In evidence review for CYP3A and CYP2C19; will be drafting guideline soon. * *NAT2*/Hydralazine – Guideline submitted and waiting for reviewer comments. * *UGT1A1*/irinotecan- Authorship plan approved; evidence review underway. * *DPYD*/fluoropyrimidines- Evidence review underway. * *TPMT-NUDT15*/thiopurines update – Will send out for member review soon. * *CYP2D6*/ondansetron - Authorship plan approved; first call soon. * *NAT2* Pharmacogene Curation Expert Panel (PCEP) – Submitted and waiting for reviewer comments. | Kelly will continue to update.  To see the guidelines currently being developed go to:  <https://cpicpgx.org/prioritization-of-cpic-guidelines/> |
| Phenotype Modifier Terminology Discussion | The modifier terminology "Likely” and "Possible” was explained, and feedback is being sought on the use and implementation of these modifier terms. | Complete [Modifier Terminology survey](https://qualtricsxmhypknk4b9.qualtrics.com/jfe/form/SV_79DAGYsgvQKXzjo) |
| ClinPGx Update | The new ClinPGx website ([www.clinpgx.org](file:///C:\Users\kcaudle\AppData\Local\Microsoft\Windows\INetCache\Content.Outlook\0BB9YP9K\www.clinpgx.org)) is in the process of being launched. The ultimate goal of the new site is to combine the PharmGKB, CPIC, and PharmCat websites into one unified platform. All functionality from the previous websites has been maintained. | Send new Clinpgx.org website feedback to [feedback@clinpgx.org](mailto:feedback@clinpgx.org?subject=ClinPGx%20Feedback) |
| *TPMT/NUDT15*-Thiopurine Guideline Update and CPIC  *TPMT/NUDT15* Pharmacogene Curation Expert Panel (PCEP) | Maud Maillard, PharmD, PhD, Postdoctoral Fellow, St. Jude Children’s Research Hospital, presented “CPIC guideline for thiopurine dosing based on *TPMT/NUDT15* genotypes: 2025 update”.  Bailey Tibben, PhD, Associate Scientist, St. Jude Children’s Research Hospital, presented  *TPMT/NUDT15* CPIC Pharmacogene Curation Expert Panel (PCEP). | Select slides posted to member site.  <https://cpicpgx.org/member-resources/conference-call-minutes/2025-cpic-conference-call-minutes/> |